Cancer drug shot preferred over IV drip in new study
NCT ID NCT06099782
First seen Apr 17, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say which they like better. The goal is to see if the shot is more convenient and comfortable, not to test if it works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 0903)
Adana, 01140, Turkey (Türkiye)
-
Alaska Oncology and Hematology ( Site 0121)
Anchorage, Alaska, 99508, United States
-
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 0901)
Ankara, 06800, Turkey (Türkiye)
-
Auckland City Hospital-Cancer & Blood Research ( Site 1051)
Auckland, 1023, New Zealand
-
Bell Land General Hospital ( Site 1101)
Sakai, Osaka, 599-8247, Japan
-
Bowen Hospital ( Site 1050)
Wellington, 6035, New Zealand
-
Bradfordhill-Clinical Area ( Site 0402)
Santiago, Region M. de Santiago, 8420383, Chile
-
CANCERCARE RONDEBOSCH ONCOLOGY-Cancercare Rondebosch Oncology ( Site 0806)
Cape Town, Western Cape, 7700, South Africa
-
CENTRE LEON BERARD-onco dermatology ( Site 0600)
Lyon Cedex08, Auvergne-Rhône-Alpes, 69373, France
-
Cancer Care Langenhoven Drive Oncology Centre ( Site 0808)
Port Elizabeth, Eastern Cape, 6045, South Africa
-
Cape Town Oncology Trials ( Site 0802)
Cape Town, Western Cape, 7570, South Africa
-
Centre Hospitalier Universitaire de Caen Normandie-DERMATOLOGY ( Site 0604)
Caen, Calvados, 14000, France
-
Centro Investigacion Cancer James Lind ( Site 0408)
Temuco, Araucania, 4800827, Chile
-
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0701)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
-
Clinique Francois Chenieux ( Site 0603)
Limoges, Haute-Vienne, 87039, France
-
Clínica Puerto Montt ( Site 0404)
Port Montt, Los Lagos Region, 5500243, Chile
-
Ege Universitesi Hastanesi ( Site 0902)
Izmir, 35100, Turkey (Türkiye)
-
FALP-UIDO ( Site 0401)
Santiago, Region M. de Santiago, 7500921, Chile
-
Frankston Hospital-Oncology and Haematology ( Site 1007)
Frankston, Victoria, 3199, Australia
-
Fundación Respirar ( Site 0302)
Buenos Aires, Buenos Aires F.D., C1426ABP, Argentina
-
HIA Sainte Anne-Pneumology ( Site 0601)
Toulon, Var, 83800 Cedex 9, France
-
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0900)
Ankara, 06230, Turkey (Türkiye)
-
Highlands Oncology Group-Research Department ( Site 0133)
Springdale, Arkansas, 72762, United States
-
Holy Cross Hospital-Clinical Research ( Site 0159)
Fort Lauderdale, Florida, 33308, United States
-
Hôpital Bichat - Claude-Bernard ( Site 0605)
Paris, Île-de-France Region, 75018, France
-
Instituto San Marcos ( Site 0305)
San Juan, J5400EBB, Argentina
-
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)
Mar del Plata, Buenos Aires, B7600FZO, Argentina
-
Kadlec Clinic Hematology and Oncology ( Site 0103)
Kennewick, Washington, 99336, United States
-
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 0800)
Pretoria, Gauteng, 0181, South Africa
-
Marin Cancer Care ( Site 0148)
Greenbrae, California, 94904, United States
-
Medical Oncology Centre of Rosebank ( Site 0805)
Johannesburg, Gauteng, 2196, South Africa
-
Mid Florida Hematology and Oncology Center ( Site 0113)
Orange City, Florida, 32763, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0112)
Marietta, Georgia, 30060, United States
-
Nosworthy Oncology ( Site 0807)
Johannesburg, Gauteng, 2196, South Africa
-
ONCOCENTRO APYS-ACEREY ( Site 0400)
Viña del Mar, Valparaiso, 2520598, Chile
-
Oncovida ( Site 0403)
Santiago, Region M. de Santiago, 7500994, Chile
-
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0407)
Santiago, Region M. de Santiago, 8330032, Chile
-
Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 1001)
Port Macquarie, New South Wales, 2444, Australia
-
Russell Medical ( Site 0160)
Alexander City, Alabama, 35010, United States
-
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0801)
Sandton, Gauteng, 2196, South Africa
-
Steve Biko Academic Hospital-Medical Oncology ( Site 0804)
Pretoria, Gauteng, 0001, South Africa
-
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0702)
Koszalin, West Pomeranian Voivodeship, 75-581, Poland
-
Tokyo Women's Medical University ( Site 1100)
Tokyo, 162-8666, Japan
-
Zachodniopomorskie Centrum Onkologii ( Site 0703)
Szczecin, West Pomeranian Voivodeship, 71-730, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab with hyaluronidase
What this could lead to
If successful, this could offer a faster, more convenient way to receive pembrolizumab as a shot instead of a lengthy IV infusion.
What could go wrong
This is an early-phase study focused on patient preference, not on whether the shot works better or is safer than the IV form. The shot may not be suitable for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.